Standards; Pharmaceutical/API Drug Impurities/Metabolites;
應(yīng)用:
N-Carbamoyl Linagliptin is a derivative of Linagliptin (L465900), a novel potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor with potential use in the treatment of type 2 diabetes.